Skip to the content

Let Tomorrow Begin Today

Innovation in Cell Therapy at MSK

The Stem Cell Transplantation Service at Memorial Sloan Kettering Cancer Center (MSK) was one of the first in the United States and has grown to become one of the largest. More than 2,500 allogeneic and 2,500 autologous bone marrow or peripheral blood stem cell transplants have been performed at this Center. Our founding physicians were pioneers in the field, completing the first transplant using bone marrow from an unrelated donor in 1974. 

MSK Scientists are also pioneers in the CAR T Cell immunotherapy breakthrough. Groundbreaking MSK studies led by Michel Sadelain, Director of MSK’s Center of Cell Engineering, and Renier Brentjens, Director of MSK’s Cellular Therapeutics, revolutionized the treatment landscape for patients with therapyrefractory lymphoma and leukemia who have received these genetically modified T cells. We are also world-renowned for innovation in:

  • Optimizing outcomes for transplantation as curative option for a variety of (mainly pediatric) non-malignant indications: e.g. primary immune deficiencies, bone marrow failure syndromes, heamoglobinopathies, inherited metabolic diseases
  • The introduction of T cell depletion as a way to prevent graft-versus-host disease (GVHD) in 1979 using soybean agglutination and E-rosetting and now with CD34 Selection. CD34 selection is now used in a number of centers worldwide and is being compared to other alternative strategies of GVHD prevention.
  • The introduction of a new total body irradiation regimen - this hyperfractionated method was developed as part of the myeloablative conditioning of patients with leukemia or lymphoma to increase the antitumor effect and decrease the short and long-term side effects of radiation. Marrow transplantation using this regimen has resulted in low posttransplant relapse rates and has also reduced the long-term effects of radiation on growth and other endocrine function
  • The implementation of novel gut microbiota research findings in the clinical setting – recent research at this Center highlights associations between bone marrow transplantation and the bacteria that naturally reside in the gut. These findings have led to clinical trials aimed at managing complications of transplant such as graft-versus-host disease (GVHD) and infection.
  • Personalizing the chemotherapy given prior to transplant to reduce toxicity and to improve survival chances

Attend the MSK Networking Event at the TCT Meetings

Are you ready to meet our team and learn about the innovation that is happening each day at MSK? Join us for a night of networking and discover how we're leading the way in Cellular Therapy 

Friday, February 22, 2019 - 7:00pm-10:00pm 

 

Expanding Our Team

Scheduled to open in November 2019, The David H. Koch Center for Cancer Care will provide a dynamic setting for leading-edge cancer treatments. The Koch Center (located between 73rd and 74th Streets, in Manhattan) re-designs the way in which cancer care is provided, with an emphasis on innovation, continuous data-driven improvement, and optimized patient experience. Our team is hiring for Faculty, Advanced Practice Providers, PharmD, Data Managers and more. 

Visit us during the TCT Meetings at Booth #2248 to learn more. 

Upcoming Events at MSK

Click on the links below for more information and to register for upcoming events. 

Clinical Application of CAR T Cells

Date03/14/2019
LocationNew York City

Memorial Sloan Kettering Cancer Alliance: 1st Advanced Practice Provider Oncology Symposium

Date03/16/2019
LocationZuckerman Research Center, New York, NY

8th Annual State-of-the-Art in Thrombosis and Hemostasis Symposium

Date09/15/2019
LocationZuckerman Research Center, New York, NY
Back to top